OVERCOMING DRUG SHORTAGES WITH TECH

August 25, 2019

Medication shortages come with a substantial cost to pharmaceutical companies—loss of revenue, provider loyalty, and brand reputation pose significant and detrimental threats to business. Currently, the United States Food and Drug Administration (U.S. FDA) lists over 150 drug shortages, costing the United States $216M in labor and $200M in substitution costs, each year.

Spotlight

Modus Therapeutics AB

Modus Therapeutics AB is a Swedish drug development company developing sevuparin, which has the potential to restore blood flow in both sickle cell disease and malaria patients. Sevuparin originates from research at the Karolinska Institute and Uppsala University.

OTHER WHITEPAPERS
news image

The SwedishDrug Discovery and DevelopmentPipeline 2023

whitePaper | March 23, 2023

Sweden is and should remain a leading life sciences nation. The life sciences industry is one of Sweden’s economic base industries with a signifi cant share of our exports.

Read More
news image

Infosys and Top Pharma Bring Digital Transformation to DrugManufacturing Data

whitePaper | April 1, 2022

In 2017, a top 20 global pharmaceutical company began a journey to digitally transform its pharmaceutical engineering and manufacturing capabilities by constructing a data integration and visualization platform, with strategic assistance and technical implementation provided by its partner Infosys.

Read More
news image

Addressing Viral Pandemics Such as COVID-19 Using the Carterra® LSA

whitePaper | January 21, 2023

Emerging Diseases Require New Tools Medicines to treat and prevent infectious diseases cover a broad range of modalities from dosed therapeutics to vaccines. Biotherapeutics require a detailed knowledge of binding sites, or epitopes, on their respective antigens.

Read More
news image

Global Use of Medicines 2023

whitePaper | January 18, 2023

Reaching a post-pandemic era is an alluring prospect for almost everyone around the world after the disruptions of the past three years.

Read More
news image

Patients Diagnosed with Post-COVID Conditions

whitePaper | May 18, 2022

Post-COVID conditions, also known by such terms as long COVID and post-acute sequelae of COVID-19, have become an issue of growing national concern.

Read More
news image

Combatting Future Viral Threats with Vaccine Advances

whitePaper | February 3, 2023

Since the beginning of the COVID-19 pandemic, pharmaceutical organizations have experienced major changes, a prime example of which has been the rising requirement for collaborations on multiple different fronts across the industry.

Read More

Spotlight

Modus Therapeutics AB

Modus Therapeutics AB is a Swedish drug development company developing sevuparin, which has the potential to restore blood flow in both sickle cell disease and malaria patients. Sevuparin originates from research at the Karolinska Institute and Uppsala University.

Events